Indirect comparison of biological treatments in refractory rheumatoid arthritis

Gallego-Galisteo, M; Villa-Rubio, A; Rey, EJ Alegre-Del; Márquez-Fernández, E; Ramos-Báez, JJ

doi:10.1111/j.1365-2710.2011.01292.x

Cited by 31 publications

(25 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effectiveness of TCZ is comparable to that of each of the TNF inhibitors with respect to ACR20 and ACR50 responses, but greater than that of the TNF inhibitors with respect to ACR70 response. Another systematic review of selected clinical trials involving combination therapy with MTX concluded that there was no difference in efficacy on the basis of ACR50 response criterion at 24/30 weeks between TNF inhibitors and TCZ 25. Turkstra et al reported a mixed treatment comparison of the short-term efficacy of nine bDMARDs, including TNF inhibitors and TCZ in patients with established RA 26.…”

Section: Comparative Efficacy Studies Of Tcz Ada and Other Tnf Inhimentioning

confidence: 99%

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors

Tanaka¹,

Hishitani²,

Ogata³

2014

BTT

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation, systemic inflammation, and immunological abnormalities. Because cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 play a major role in the development of RA, their targeting could constitute a reasonable novel therapeutic strategy for treating RA. Indeed, worldwide clinical trials of TNF inhibiting biologic disease modifying antirheumatic drugs (bDMARDs) including infliximab, adalimumab, golimumab, certolizumab pegol, and etanercept as well as the humanized anti-human IL-6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bDMARDs to treat moderate to severe active RA in patients with an inadequate response to synthetic disease modifying antirheumatic drugs (sDMARDs). Although bDMARDs have elicited to a paradigm shift in the treatment of RA due to the prominent efficacy that had not been previously achieved by sDMARDs, a substantial percentage of patients failed primary or secondary responses to bDMARD therapy. Because RA is a heterogeneous disease in which TNF-α and IL-6 play overlapping but distinct pathological roles, further studies are required to determine the best use of TNF inhibitors and tocilizumab in individual RA patients.

show abstract

Section: Comparative Efficacy Studies Of Tcz Ada and Other Tnf Inhimentioning

confidence: 99%

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors

Tanaka¹,

Hishitani²,

Ogata³

2014

BTT

View full text Add to dashboard Cite

show abstract

“…Recently biological agents (biologics), especially tumor necrosis factor antagonists (anti-TNFs, TNF-i), have demonstrated considerable efficacy in treating patients with RA who do not respond or show intolerance to traditional DMARDs [1-3]. Many randomized controlled trials (RCTs) comparing their efficacy with placebo treatment in DMARD-refractory patients have been published, as well as systematic reviews (SRs) and overviews of SRs of these RCTs [4].…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

Choi

Hyun

Choi³

et al. 2017

Korean J Intern Med

View full text Add to dashboard Cite

Background/AimsBiological agents (biologics) targeting proinflammatory signaling have emerged as an important treatment option in rheumatoid arthritis (RA). Despite the clinical effectiveness of biologics for patients with RA who do not respond to ‘traditional’ disease-modifying anti-rheumatic drugs (DMARDs), there are concerns regarding their cost and long-term safety. In this study, we aimed to compare the efficacy of various biologics and traditional DMARDs in RA patients refractory to methotrexate (MTX).MethodsFour DMARDs (hydroxychloroquine, sulfasalazine, MTX, lef lunomide) and five anti-tumor necrosis factor drugs (adalimumab, etanercept, golimumab, inf liximab, and certolizumab) were selected. A systematic search of published studies was performed from inception through July 2013. Randomized trials of adults with MTX-refractory RA comparing two or more of the selected medications were included. Among 7,938 titles identified, in total, 16 head-to-head trials were selected. Two reviewers independently abstracted the study data and assessed methodological quality using the Cochrane Risk of Bias. Comparative efficacy was analyzed using a Bayesian mixed treatment comparison (MTC).ResultsIn total, 9, 4, and 11 studies were included for the outcome measures of the Health Assessment Questionnaire (HAQ), Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) < 2.6 (remission), and American College of Rheumatology (ACR) 70 response, respectively. The treatments with the highest efficacy for each outcome measure were certolizumab combined with MTX, golimumab combined with MTX, and certolizumab combined with MTX, respectively.ConclusionsBased on MTC analysis, using data from published randomized controlled trials, certolizumab and golimumab combined with MTX showed the highest efficacy in the three outcome measures (HAQ, DAS28-ESR < 2.6, and ACR 70 response) in MTX-refractory RA patients.

show abstract

“…Изучены Национальные рекомендации по лечению РА [4], в которых дается заключение об отсутст-вии значимого различия в эффективности [1][2][3] и то-ксичности [26][27][28][29] различных ГИБП. Сообщается, что у па-циентов с РА, резистентных к стандартным БПВП, препара-тами выбора являются ингибиторы фактора некроза опухо-ли (ФНО) α, однако в качестве первого ГИБП возможно на-значение абатацепта (АБЦ), ритуксимаба (РТМ) и тоцили-зумаба (ТЦЗ), которые, согласно результатам систематиче-ских обзоров, не отличаются по эффективности и безопас-ности от ингибиторов ФНОα (уровень доказательности А) [2,3,[5][6][7][8][16][17][18][19][20][21][22][23][24][25]. Аналогичные выводы о равной эффектив-ности ГИБП, применяемых в лечении РА у пациентов, рези-стентных к терапии метотрексатом (МТ) и другими БПВП [29,30], сделаны отечественными авторами [31].…”

unclassified

“…[22], посвящен-ном эффективности различных ГИБП у больных РА, для не-прямого сравнения эффективности этих препаратов отобраны 10 рандомизированных плацебоконтролируемых исследова-ний, демонстрирующих частоту ответа по критериям Амери-канской коллегии ревматологов (ACR) к 24-30-й неделе лече-ния. Авторами сделано заключение об отсутствии различий в эффективности ГИБП, применяемых для лечения РА.…”

unclassified

“…[32] на основании результатов многочисленных систематических обзоров ли-тературы и метаанализов РПКИ, касающихся оценки эф-фективности применения ТЦЗ и других ГИБП [17,18,22,24,[33][34][35][36], сделали заключение об отсутствии различий в их эффективности, если ГИБП применялись в комбинации с МТ. Также авторы отмечают, что ТЦЗ может быть более эффективен, чем ингибиторы ФНОα, в режиме монотера-пии, когда сопутствующая терапия БПВП не применяется.…”

unclassified

See 1 more Smart Citation

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis

Dyakov¹,

Goryachev²

2014

RJTAO

View full text Add to dashboard Cite

show abstract

Indirect comparison of biological treatments in refractory rheumatoid arthritis

Abstract: The biological drugs used in rheumatoid arthritis are no different in efficacy. Their therapeutic positioning depends on their relative safety and convenience profiles.

Cited by 31 publications

References 22 publications

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors

Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors

Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis

Contact Info

Product

Resources

About